Ozcan Gulbahar Boyuk, Bozok Ummu Gulsen
Department of Physiology, Ankara Medipol University Faculty of Medicine;
Department of Physiology, Ankara Medipol University Faculty of Medicine.
J Vis Exp. 2025 Aug 1(222). doi: 10.3791/68066.
The use of islet-like cells derived from ductal cells has emerged as a potential approach for treating type 1 diabetes. Diabetic patients have insufficient insulin synthesis in their bodies due to the autoimmune destruction of pancreatic beta cells responsible for making insulin. Within this framework, the objective of islet cell transplantation is to reinstate the ability of patients to produce insulin. However, obstacles such as the insufficient acquisition of islet cells from donor pancreases and immune reactions hinder the broad application of this therapy method. Under specific circumstances, pancreatic ductal cells possess the capability to transform into cells that produce insulin. These cells could be cultivated in a controlled environment and converted into islet-like cells that have the capability to release insulin, making them suitable for transplantation. This innovative strategy offers the potential to halt the progression of type 1 diabetes and reduce dependence on insulin injections. In this study, islet-like cells derived from ductal cells were transplanted into the liver through the portal vein of the liver in streptozotocin-induced diabetic rats. Following transplantation, we noted substantial reductions in the rats' blood glucose levels starting on day 5, which continued for 15 days. In addition, an intraperitoneal glucose tolerance test (IPGTT) demonstrated that diabetic rats receiving the islet-like cell transplants produced significantly more insulin than the control group. These results suggest that islet-like cells derived from ductal cells may be a promising therapeutic approach for diabetes. The primary obstacles in this field of study include achieving sufficient functional capability for the cells, shielding them from the immune system, and ensuring their safety for therapeutic application. Future studies endeavors have the potential to yield crucial insights for optimizing the use of these cells in therapeutic settings, with a focus on enhancing both efficacy and safety.
利用源自导管细胞的类胰岛细胞已成为治疗1型糖尿病的一种潜在方法。糖尿病患者由于负责产生胰岛素的胰腺β细胞受到自身免疫破坏,体内胰岛素合成不足。在此背景下,胰岛细胞移植的目标是恢复患者产生胰岛素的能力。然而,诸如从供体胰腺获取胰岛细胞不足以及免疫反应等障碍阻碍了这种治疗方法的广泛应用。在特定情况下,胰腺导管细胞具有转化为产生胰岛素的细胞的能力。这些细胞可以在可控环境中培养并转化为具有释放胰岛素能力的类胰岛细胞,使其适合移植。这种创新策略有可能阻止1型糖尿病的进展并减少对胰岛素注射的依赖。在本研究中,将源自导管细胞的类胰岛细胞通过肝门静脉移植到链脲佐菌素诱导的糖尿病大鼠的肝脏中。移植后,我们注意到从第5天开始大鼠血糖水平大幅下降,并持续了15天。此外,腹腔葡萄糖耐量试验(IPGTT)表明,接受类胰岛细胞移植的糖尿病大鼠产生的胰岛素明显多于对照组。这些结果表明,源自导管细胞的类胰岛细胞可能是一种有前途的糖尿病治疗方法。该研究领域的主要障碍包括使细胞获得足够的功能能力、使其免受免疫系统影响以及确保其治疗应用的安全性。未来的研究努力有可能为优化这些细胞在治疗环境中的使用提供关键见解,重点是提高疗效和安全性。